Preferred Label : Motacabtagene Lurevgedleucel;
NCIt synonyms : CRISPR/Cas9 Gene-edited Allogeneic Anti-BCMA CAR-T Cells CTX120; Allogeneic CRISPR-Cas9 Engineered Anti-BCMA T Cells CTX120;
NCIt definition : A preparation of human allogeneic T-lymphocytes gene-edited with the clustered regularly
interspaced short palindromic repeats (CRISPR)-Cas9 nuclease complex to disrupt expression
of endogenous TCR and major histocompatibility complex (MHC) class I molecules and
modified to express a chimeric antigen receptor (CAR) specific for the tumor-associated
antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor
superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic
activities. Upon introduction into the patient, motacabtagene lurevgedleucel recognize
and bind to BCMA-overexpressing tumor cells. This may result in a specific cytotoxic
T-lymphocyte (CTL)-mediated killing of BCMA-positive tumor cells. BCMA, a receptor
for proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is
a member of the tumor necrosis factor (TNF) receptor superfamily (TNFRSF) and plays
a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells
and overexpressed on malignant plasma cells. The disruption of endogenous TCR prevents
graft-versus-host disease (GvHD). The disruption of MHC class I molecules increases
the persistence of the CAR T-cells.;
UNII : 7CH7MR6SN5;
Molecule name : CTX 120; CTX-120;
NCI Metathesaurus CUI : CL1406620;
Origin ID : C172741;
UMLS CUI : C5783387;
Semantic type(s)
- Cell [UMLS semantic type]
- concept_is_in_subset
- has_target
